INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

INmune Bio (NASDAQ:INMB) issued its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.14, Zacks reports.

INmune Bio Price Performance

INMB stock traded down $0.16 during midday trading on Friday, reaching $7.25. 80,459 shares of the stock were exchanged, compared to its average volume of 241,358. INmune Bio has a 52 week low of $4.32 and a 52 week high of $12.72. The company has a fifty day moving average price of $8.39 and a 200 day moving average price of $6.37. The stock has a market capitalization of $192.86 million, a PE ratio of -3.28 and a beta of 1.93.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Maxim Group increased their price target on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Rodman & Renshaw began coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Scotiabank lifted their price target on INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Tuesday, February 11th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $22.80.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.